AL Amyloidosis: Clinical Trials

27 trials for AL Amyloidosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 completed, 6 recruiting, 5 active not recruiting, 3 terminated. 27 Phase 2, 8 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 227Completed 9, Recruiting 6, Active not recruiting 5, Terminated 3, Not yet recruiting 2, Unknown 1, Withdrawn 1
Phase 18Completed 4, Recruiting 2, Active not recruiting 1, Withdrawn 1

Follow AL Amyloidosis: new trials by email Literature Review of AL Amyloidosis trials Research Report on AL Amyloidosis

Trials (filtered) newest first · largest first

All 27 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
BCMA/GPRC5D Trispecific Antibody Treatment for Newly Diagnosed Amyloidosis (AL-004)
QLS4131 - AL Amyloidosis
Phase 2Not yet recruitingInstitute of Hematology & Blood Diseases Hospital, China202026-07-202026-08-07
A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).
Teclistamab - Multiple Myeloma, AL Amyloidosis
Phase 2RecruitingShanghai Zhongshan Hospital302026-05-222026-08-03
A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis
Teclistamab - AL Amyloidosis
Phase 2Active not recruitingEuropean Myeloma Network B.V.302025-07-022026-07-20
Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL Amyloidosis
Eque-cel CAR-T Therapy - AL Amyloidosis
Phase 2Not yet recruitingNanjing IASO Biotechnology Co., Ltd.172025-07-012025-07-09
Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis
Teclistamab (Tec) - AL Amyloidosis
Phase 2RecruitingPeking Union Medical College Hospital352025-06-282025-07-23
Teclistamab in Previously Treated AL Amyloidosis
Teclistamab (Tec) - AL Amyloidosis
Phase 2RecruitingPeking Union Medical College Hospital302025-05-212025-05-25
Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis
Elranatamab - AL Amyloidosis
Phase 1 / Phase 2RecruitingDana-Farber Cancer Institute492024-11-012026-08-19
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
Belantamab mafodotin 2.5 mg/kg (8 weeks), Belantamab mafodotin 1.9 mg/kg (8 weeks), Belantamab mafodotin 1.4 mg/kg (12 weeks) - AL Amyloidosis, Amyloidosis
Phase 1 / Phase 2RecruitingUniversity of Texas Southwestern Medical Center372024-02-152026-08-19
Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)
Venetoclax, Dexamethasone, Daratumumab - AL Amyloidosis, Light Chain (AL) Amyloidosis
Phase 1 / Phase 2WithdrawnAlfred Chung, MD2024-01-082025-03-06
Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial
Bone Marrow Aspiration, Daratumumab, Echocardiography Test - AL Amyloidosis
Phase 2RecruitingMayo Clinic962023-09-062026-10-01
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
Venetoclax Oral Tablet, 200 mg, FISH assay, Venetoclax Oral Tablet, 400 mg - AL Amyloidosis
Phase 1 / Phase 2Active not recruitingColumbia University532022-10-262026-10-08
Isatuximab Plus Pomalidomide and Dexamethasone Association for Patients With AL Amyloidosis Not in VGPR or Better After Any Previous Therapy
Isatuximab - AL Amyloidosis
Phase 2UnknownIntergroupe Francophone du Myelome462022-02-112024-03-06
Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis
ZN-d5 - Amyloidosis, AL Amyloidosis
Phase 1 / Phase 2CompletedK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.182021-11-302024-09-19
COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies
A single "booster" dose of the Moderna mRNA COVID-19 vaccine - Multiple Myeloma, AL Amyloidosis
Phase 2CompletedBarbara Ann Karmanos Cancer Institute1192021-08-172023-12-20
Daratumumab and Pomalidomide in Previously Treated Patients With AL Amyloidosis
daratumumab and pomalidomide - AL Amyloidosis
Phase 2TerminatedFondazione IRCCS Policlinico San Matteo di Pavia272021-06-232025-02-20
Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
Daratumumab SC, Pomalidomide, Dexamethasone - Amyloid, AL Amyloidosis
Phase 2Active not recruitingWeill Medical College of Cornell University152021-04-142026-02-27
A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis
Belantamab mafodotin - AL Amyloidosis
Phase 2CompletedStichting European Myeloma Network352021-02-262026-07-31
A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis
CAEL-101, SoC: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD), Daratumumab - AL Amyloidosis
Phase 2CompletedAlexion Pharmaceuticals, Inc.252020-03-182025-03-05
Ixazomib Maintenance Study in Patients With AL Amyloidosis
Ixazomib, Dexamethasone - AL Amyloidosis
Phase 2Active not recruitingMemorial Sloan Kettering Cancer Center172018-08-022025-12-04
Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis
Siltuximab, The M.D. Anderson Symptom Inventory (MDASI) - Multiple Myeloma, AL Amyloidosis
Phase 2Active not recruitingMemorial Sloan Kettering Cancer Center302017-12-142026-11-05

Showing 20 of 27. Sign in to see all of them.

Narrower conditions

Immunoglobulin Light-chain Amyloidosis (27)  ·  Amyloidosis (6)  ·  Alzheimer Disease (3)  ·  Multiple Myeloma (3)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (1)  ·  Neoplasms, Plasma Cell (1)  ·  Paraproteinemias (1)  ·  Proteostasis Deficiencies (1)

Broader conditions

Immune System Diseases (27)  ·  Immunoproliferative Disorders (27)  ·  Lymphoproliferative Disorders (27)  ·  Metabolic Diseases (27)  ·  Neoplasms (27)  ·  Neoplasms by Histologic Type (27)  ·  Nutritional and Metabolic Diseases (27)  ·  Neoplasms, Plasma Cell (26)  ·  Paraproteinemias (26)  ·  Proteostasis Deficiencies (26)  ·  Amyloidosis (21)  ·  Blood Protein Disorders (4)  ·  Hematologic Diseases (4)  ·  Hemic and Lymphatic Diseases (4)  ·  Brain Diseases (3)

Interventions

Dexamethasone (9)  ·  daratumumab (7)  ·  pomalidomide (5)  ·  Calcium Dobesilate (3)  ·  birtamimab (3)  ·  ixazomib (3)  ·  Bendamustine Hydrochloride (2)  ·  Focal Adhesion Protein-Tyrosine Kinases (2)  ·  belantamab mafodotin (2)  ·  venetoclax (2)  ·  Biological Assay (1)  ·  Bortezomib (1)  ·  Cyclophosphamide (1)  ·  Drug Evaluation (1)  ·  In Situ Hybridization (1)

Sponsors

Prothena Biosciences Ltd. (3)  ·  Boston Medical Center (2)  ·  Columbia University (2)  ·  Memorial Sloan Kettering Cancer Center (2)  ·  Peking Union Medical College Hospital (2)  ·  Alexion Pharmaceuticals, Inc. (1)  ·  Alfred Chung, MD (1)  ·  Barbara Ann Karmanos Cancer Institute (1)  ·  Dana-Farber Cancer Institute (1)  ·  European Myeloma Network B.V. (1)  ·  Fondazione IRCCS Policlinico San Matteo di Pavia (1)  ·  Icahn School of Medicine at Mount Sinai (1)  ·  Institute of Hematology & Blood Diseases Hospital, China (1)  ·  Intergroupe Francophone du Myelome (1)  ·  K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. (1)

Countries

United States (17)  ·  Italy (6)  ·  France (5)  ·  Greece (5)  ·  Australia (4)  ·  China (4)  ·  Germany (4)  ·  Israel (3)  ·  Spain (3)  ·  United Kingdom (3)  ·  Austria (2)  ·  Netherlands (2)  ·  Cyprus (1)

Top investigators

Vaishali Sanchorawala, MD (2)  ·  Alfred Chung, MD (1)  ·  Giada Bianchi (1)  ·  Gunjan Shah (1)  ·  Heather Landau, MD (1)  ·  Jeffrey A. Zonder, M.D. (1)  ·  Keren Osman, MD (1)  ·  Larry Anderson, MD (1)  ·  Murielle Roussel, MD (1)  ·  Peng Liu (1)  ·  Rajshekhar Chakraborty, MD (1)  ·  Suzanne Lentzsch, MD, PhD (1)

Results publications

PMID 40226119, PMID 27381904, PMID 31978210, PMID 32083996

NIH funding

R21CA288898 (1)